- Home
- ACRV vs IPHA Comparison
ACRV vs IPHA Comparison
Compare ACRV & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRV
- IPHA
- Stock Information
- Founded
- ACRV 2018
- IPHA 1999
- Country
- ACRV United States
- IPHA France
- Employees
- ACRV N/A
- IPHA N/A
- Industry
- ACRV Medicinal Chemicals and Botanical Products
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- ACRV Health Care
- IPHA Health Care
- Exchange
- ACRV Nasdaq
- IPHA Nasdaq
- Market Cap
- ACRV 203.9M
- IPHA 178.0M
- IPO Year
- ACRV 2022
- IPHA 2019
- Fundamental
- Price
- ACRV $6.60
- IPHA $2.07
- Analyst Decision
- ACRV Strong Buy
- IPHA Strong Buy
- Analyst Count
- ACRV 5
- IPHA 1
- Target Price
- ACRV $22.40
- IPHA $11.50
- AVG Volume (30 Days)
- ACRV 63.5K
- IPHA 1.5M
- Earning Date
- ACRV 11-13-2024
- IPHA 09-12-2024
- Dividend Yield
- ACRV N/A
- IPHA N/A
- EPS Growth
- ACRV N/A
- IPHA N/A
- EPS
- ACRV N/A
- IPHA N/A
- Revenue
- ACRV N/A
- IPHA $36,202,722.00
- Revenue This Year
- ACRV N/A
- IPHA N/A
- Revenue Next Year
- ACRV N/A
- IPHA $102.87
- P/E Ratio
- ACRV N/A
- IPHA N/A
- Revenue Growth
- ACRV N/A
- IPHA N/A
- 52 Week Low
- ACRV $3.19
- IPHA $1.29
- 52 Week High
- ACRV $11.90
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- ACRV 42.20
- IPHA 53.12
- Support Level
- ACRV $6.56
- IPHA $1.47
- Resistance Level
- ACRV $7.45
- IPHA $2.36
- Average True Range (ATR)
- ACRV 0.47
- IPHA 0.32
- MACD
- ACRV -0.00
- IPHA 0.06
- Stochastic Oscillator
- ACRV 28.12
- IPHA 29.99
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.